Trillium Therapeutics (TSX:TRIL): A Pharma Stock With Huge Upside Potential

Trillium Therapeutics is a pharmaceutical company with massive upside potential for its innovative cancer treatment therapies.

Trillium Therapeutics (TSX:TRIL)(NASDAQ: TRIL) is a Canadian pharmaceutical stock that has massive upside potential and should be on your radar right now. The clinical-stage immuno-oncology company is developing revolutionary cancer treatment therapies, and it could be an excellent value pick for investors today.

I will discuss the company and why its stock could be an ideal investment for you to consider.

A leading innovator in oncology

Trillium Therapeutics may not be as big a name as Pfizer, but it is not a company to shrug aside. The company aims to become a leading innovator in oncology by using innovative therapies targeting immune-regulatory pathways used by tumour cells to steer clear of the immune system.

Trillium has a comprehensive and differentiated approach to targeting cancer cell therapy. The company is currently focusing on advancing the clinical development of TTI-621 and TTI-22 — two of its most advanced products for its innovative cancer cell treatment therapy.

The company is currently trying to determine the maximum tolerated doses for both products. Trillium is aiming to focus its clinical programs based on promising results for both products.

Trillium has identified that its fusion proteins can be effective in treating a wide range of cancers. CD47 is a type of immunoglobulin that exists on the surface of many cancer cells. This immunoglobulin is expressed by several solid and liquid tumours. Typically, the high expression is correlated with worse clinical outcomes.

Trillium has already identified several cancers that saw positive responses in patients to TTI-621. Considering the promising signs displayed by TTI-621, Trillium is planning to combine both products with other anti-cancer drugs and evaluate the performance of its cancer treatment therapies.

Patented-protected intellectual property

It is safe to say that Trillium owns intellectual property that could be priceless. It owns and controls patent rights covering key products and therapeutic end uses. Trillium has multiple patents and patent applications either approved or pending approval in major pharmaceutical markets worldwide. The company’s hoard patents include inventions in different areas that could give it the edge in the industry.

Trillium primarily owns two patent families. The first one relates to the applications for TTI-621 and TTI-622 for cancer treatment. The other patent family is related to the company’s drug as a composition of matter. The company has also filed for patents that protect additional inventions related to both its major products, including anti-cancer drug combination therapies that use biomarkers to determine responders.

Expert regulatory process navigation

Trillium has filed patent applications within corresponding jurisdictions worldwide to protect its intellectual property. Its expertise in navigating regulatory processes has allowed Trillium to gain approvals throughout the U.S., Europe, Canada, and other commercial territories. The company has a competitive edge over its peers.

Foolish takeaway

Trillium is not as massive a name in the international Big Pharma industry. However, the stock could be valuable for long-term investors if the company successfully develops its innovative cancer treatment therapies.

If you are bullish on its ability to succeed, it could be an excellent value investment for your portfolio.

Fool contributor Adam Othman has no position in any of the stocks mentioned.

More on Investing

a man relaxes with his feet on a pile of books
Dividend Stocks

5 of the Best Canadian Dividend Stocks to Buy This Month

These best Canadian dividend stocks have reliable distribution payment and growth histories, and sustainable payouts.

Read more »

warehouse worker takes inventory in storage room
Dividend Stocks

This 5.6% Dividend Stock Pays Cash Every Single Month

This TSX-listed monthly dividend stock’s attractive 5.6% dividend yield, growing rental income, and expanding property portfolio could make it a…

Read more »

Trans Alaska Pipeline with Autumn Colors
Energy Stocks

TFSA Income: A Solid Dividend Stock Down 15% to Buy Before It Bounces Back

This stock has increased its dividend annually for more than three decades.

Read more »

Aircraft Mechanic checking jet engine of the airplane
Dividend Stocks

Exchange Income vs. Cargojet: Which Aviation Stock Fits a Long-Term Portfolio?

Both businesses depend on keeping aircraft busy. Exchange Income’s mix of essential routes and manufacturing gives it the edge for…

Read more »

The TFSA is a powerful savings vehicle for Canadians who are saving for retirement.
Investing

3 Top Stocks for TFSA Investors to Buy Now

These stocks can help you avoid selling at a loss by prioritizing high-quality companies with sustainable growth prospects.

Read more »

man touches brain to show a good idea
Dividend Stocks

1 No Brainer Canadian Stock to Buy and Hold Forever

CN stock is up 35% in 2026, yet Q3 earnings jumped 18% on only 4% more volume. See why this…

Read more »

Agricultural irrigation sprinkler gun spraying water
Dividend Stocks

1 Magnificent Canadian Dividend Stock Down 28% to Buy and Hold for Decades

Nutrien (TSX:NTR) stock still stands out as a magnificent play that could help boost dividend investors portfolios over time.

Read more »

man calculates finances
Dividend Stocks

What $50,000 Across 3 Dividend Stocks Could Add to Your Retirement Budget

A utility, a pipeline and a railway show how $50,000 could start paying part of the retirement budget.

Read more »